Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

NhTherAguix: NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy

05/31/2021 | 05:27am EDT
NhTherAguix / Key word(s): Statement 
NhTherAguix: NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human 
phase 1 clinical trial on the combination of AGuIX with radiotherapy 
31-May-2021 / 11:26 CET/CEST 
=---------------------------------------------------------------------------------------------------------------------- 
 
 
 
 
PRESS RELEASE 
 
NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical 
trial on the combination of AGuIX with radiotherapy on multiple brain metastases patients. 
 
Grenoble (France), May 31, 2021 - 11:00 pm (CET) 
NH TherAguix ("NHT"), a clinical stage company developing innovative nanomedicines for the treatment of cancer, and the 
CHU Grenoble Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the 
combination of AGuIX, its candidate drug, with radiotherapy on multiple brain metastases patients, by Verry Camille et 
al., in Radiotherapy & Oncology medical journal.[1] 
 
This First-In-Man NANORAD trial led by the Grenoble Alpes University Hospital (principal investigator Dr. Camille 
Verry, Radiotherapy Department), allowed to assess favourably AGuIX in terms of tolerance after intravenous 
administration in combination with whole brain radiation therapy in patients with multiple brain metastases not 
suitable for stereotactic radiotherapy. Five dose levels (15, 30, 50, 75 and 100 mg/kg) have been successfully tested 
on 15 patients with a total of 354 brain metastases from 4 types of primary cancers (melanoma (n=6), lung cancer (n=6), 
colon cancer (n=1) and breast cancer (n=2). All patients have received one intravenous injection of AGuIX associated 
with a conventional whole brain radiation therapy (10 x 3 Gy). 
 
This trial has demonstrated that the combination of AGuIX with radiotherapy for these patients is safe and feasible. 
Thus, the dose of 100 mg/kg, reached without occurrence of dose limiting toxicities, was selected for the phase II 
trial that is currently ongoing. The pharmacokinetic study has confirmed the distribution of AGuIX and its renal 
elimination. AGuIX specifically targets brain metastases and is retained within tumors for up to 1 week, allowing 
radiosensitization during the fractionation of the treatment. Finally, a clinical benefit according RECIST v1.1 
(partial response or stable disease) was proven for 13 over 14 evaluable patients. MRI analysis also showed a 
significant correlation between contrast enhancement and tumor response, thus supporting a radiosensitizing effect. 
 
A first scientific publication on the same trial and already published[2] explains in more details the targeting of 
brain metastases by accumulation of AGuIX. Beyond the qualitative aspect, it was possible to quantify the concentration 
of nanoparticles revealing the potential of AGuIX to be used as a theranostic drug allowing to quantify the 
radiosensitization prior to radiotherapy. 
 
For patients with multiple brain metastases, despite advances in stereotactic radiosurgery and new systemic treatments 
(immunotherapy and targeted therapy for example), estimates of overall survival at 2 years and at 5 years for all types 
of primary tumors are approximately 8% and 2% respectively. Consequently, there is still a huge unmet medical need for 
these patients. 
 
 
Dr. Camille Verry, principal investigator of this clinical trial and national coordinator of the ongoing NANORAD 2 
multicenter trial reports: 
"The results of this phase 1 study are very encouraging, with the demonstration of a favorable tolerance of AGuIX as a 
candidate drug in humans and a remarkable distribution in brain metastases. The simplicity of the intravenous use of 
these nanoparticles combined with first elements in favor of a radiosensitizing effect allow to think that AGuIX could 
be a drug of choice in the future for neuro-oncology, if results are confirmed". 
 
 
Markus Loeffler, Chief Medical Officer of NHT, comments: 
"Following this trial, the company entered phase 2 with 2 clinical trials focusing on radiotherapy of brain metastases, 
either by whole brain radiation therapy (NANORAD 2), or in a complementary manner by stereotactic radiosurgery/ 
radiotherapy (NANOBRAINMETS). NANORAD 2 is a French multicenter randomized trial (100 patients) piloted by the CHU 
Grenoble Alpes (p.i. Dr Camille Verry). It combines whole brain radiation therapy with 3 intravenous injections of 
AGuIX at 100 mg/kg. NANOBRAIMETS is a trial (134 patients) led by the Dana Farber Cancer Institute - Harvard (p.i. Dr 
Ayal Aizer). In this trial, stereotactic radiation is combined with 2 intravenous injections of AGuIX at 100 mg/kg, to 
have better tumor control and increase patient survival". 
 
 
=---------------------------------------------- 
 
About AguIX 
The drug candidate AGuIX, whose potential efficacy is based on nanoscale structuring, is administered by intravenous 
injection. It combines three essential assets to fight tumors and accessible from the same injection: target, image and 
treat. AGuIX technology is therefore part of the theranostic concept which corresponds to a combination of therapy 
(radiosensitizing effect) and diagnosis (visible in MRI), and more broadly in the personalized medicine of tomorrow, 
without changing the patient's care path. Due to its biodistribution and mode of action, the nanomedicine AGuIX has a 
broad spectrum of action against solid tumors, 60% of which are treated by radiotherapy. 
 
 
About the company NH TherAguix (www.nhtheraguix.com) 
NH TherAguix is ??a French biotech start-up based in Grenoble and created in 2015 by two co-founding scientists, Prof 
Olivier Tillement (Scientific advisor of NH TherAguix and Director of the Fennec team, Institute Lumière Matière, 
University of Lyon 1) and Géraldine Le Duc (CEO of NH TherAguix), after 10 years of preclinical research. The 
technology of the drug candidate AGuIX is supported by 14 patent families and more than 70 scientific publications. The 
production of AGuIX is handled by partners such as Sanofi and Carbogen. The team currently consists of 19 people and 
its board of directors is chaired by Hervé Brailly (Co-founder and current chairman of the supervisory board of Innate 
Pharma). The company is pursuing its strategy ambitiously as it is currently focused on its clinical development in the 
USA and on the preclinical development of a second-generation drug. 
 
 
About CHU Grenoble Alpes  (www.chu-grenoble.fr) 
In the Top 10 of the best hospitals in France, CHU Grenoble Alpes (CHUGA) is the benchmark and referral institution for 
hospitals in the Alpine Arc. With more than 10,000 professionals, the CHUGA welcomes 900,000 patients each year. 
Efficient in all medical specialties and with state-of-the-art equipment, the CHUGA has many areas of excellence, both 
in medical care and in research. It is the first French university hospital to be certified at level A in its entirety 
and in first intention by the college of the High Authority of Health (HAS). The CHU Grenoble Alpes has great potential 
in many research fields on which its scientific notoriety is based. With more than 1,400 clinical research protocols in 
active file, more than 1,000 new publications and 5,000 healthy patients and volunteers included each year, the 
Delegation for Clinical Research and Innovation at CHU Grenoble Alpes ranks 12th nationally. 
 
 
 
Contacts : 
Géraldine Le Duc       Isabelle Dray 
CEO & Co-founder       Press Relations 
leduc@nhtheraguix.com  idray@actifin.fr ----------------------------------------------------------------------------------------------------------------------- 

[1] Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial). Verry C, Dufort S, Villa J, Gavard M, Iriart C, Grand S, Charles J, Chovelon B, Cracowski JL, Quesada JL, Mendoza C, Sancey L, Lehmann A, Jover F, Giraud JY, Lux F, Crémillieux Y, McMahon S, Pauwels PJ, Cagney D, Berbeco R, Aizer A, Deutsch E, Loeffler M, Le Duc G, Tillement O, Balosso J. Radiother Oncol. 2021 May 4:S0167-8140 (21)..

[2]Targeting brain metastases with ultrasmall theranostic nanoparticles, a first-in-human trial from an MRI perspective. Verry C, Dufort S, Lemasson B, Grand S, Pietras J, Troprès I, Crémillieux Y, Lux F, Mériaux S, Larrat B, Balosso J, Le Duc G, Barbier EL, Tillement O. Sci Adv. 2020 Jul 15; 6(29). -----------------------------------------------------------------------------------------------------------------------

Dissemination of a Financial Wire News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Issuer:       NhTherAguix 
              29 chemin du vieux Chêne 
              38240 Meylan 
              France 
Phone:        0476041456 
E-mail:       cruz@nhtheraguix.com 
Internet:     www.nhtheraguix.com 
EQS News ID:  1202537 
 
End of Announcement - EQS News Service 
=------------------------------------------------------------------------------------ 

1202537 31-May-2021 CET/CEST

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1202537&application_name=news 
 

(END) Dow Jones Newswires

May 31, 2021 05:26 ET (09:26 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
CRAZY SPORTS GROUP LIMITED -14.66% 0.495 End-of-day quote.70.69%
DJ INDUSTRIAL -0.24% 35058.52 Delayed Quote.14.56%
INNATE PHARMA 2.33% 2.718 Real-time Quote.-23.28%
SANOFI -0.17% 86.97 Real-time Quote.10.70%
SIMPLICITY HOLDING LIMITED -2.38% 1.64 End-of-day quote.1,181.25%
Latest news "Companies"
06:43aPROSPERITY BANCSHARES : Q2 Earnings Snapshot
AQ
06:43aSTRATEGIC EDUCATION : Q2 Earnings Snapshot
AQ
06:43aBARCLAYS : JP Morgan remains its Buy rating
MD
06:42aDYNATRACE, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
06:41aIndian shares end down as pharma stocks fall, Fed meeting in focus
RE
06:41aRIO TINTO : Buy rating from JP Morgan
MD
06:41aBlip or bad moon rising? Fed meets amid COVID-19 surge, inflation jitters
RE
06:40aEAGLE MATERIALS : Fiscal Q1 Earnings Snapshot
AQ
06:38aABB LTD : Credit Suisse sticks Neutral
MD
06:38aImplats Says Fiscal Year 2021 Earnings Rose by at Least 20%
DJ
Latest news "Companies"